The National Cancer Institute is soliciting proposals from small business concerns to perform key activities to demonstrate technical feasibility and proof-of-concept for the development of highly innovative and potentially transformative technologies in the following areas: Development of therapeutic technologies for treatment or prevention of Pediatric Cancers and/or Rare Cancers. Development of devices or diagnostic technologies for treatment, detection, and diagnosis of Pediatric Cancers and/or Rare Cancers. For this solicitation rare cancers with a 5-year survival rate of less than 50 % are encouraged and rare cancers would be defined as including all the cancers listed by the NIH Genetics and Rare Diseases Information Center. The list can be found here: https://rarediseases.info.nih.gov/diseases/diseases-by-category/1/rare-cancers. Access the NCI Surveillance, Epidemiology, and End Results Program (SEER) database (https://seer.cancer.gov/) for more information regarding 5-year cancer survival rates. Preliminary data is not required; however, the ideas should have sound scientific premise either based on the offeror’s own research or literature evidence. Proposals will need to identify an anticipated product that will be developed and clearly lay out the anticipated development path. Proposals will need to clearly identify the clinical problem and cancer type(s) that the proposal will focus on with adequate justification. In addition, the offerors should propose experiments to obtain initial de-risking and proof-of-concept data. Awards will also include requirements to enhance entrepreneurship skills and to develop or refine a business model and commercialization plan. This solicitation is a Concept Award program that could serve as a pipeline for the federal Small Business Innovation Research (SBIR) program. Background for the SBIR program can be found in the Small Business Administration’s policy directive found here: https://www.sbir.gov/sites/default/files/SBA_SBIR_STTR_POLICY_DIRECTIVE_OCT_2020_v2.pdf The RFP is anticipated to result in approximately 5-10 awards. NCI will make awards to the offerors based on the following considerations: Technical Evaluation; Areas of high program relevance; Program balance (i.e., balance among areas of research); Availability of funds; and, Cost/Price reasonableness. Awards are anticipated in February 2024. Awards are anticipated to be Firm Fixed Price (FFP). The duration of the contract(s) is anticipated to be twelve (12) months with a budget up to $300,000. This advertisement does not commit the United States Federal Government to award any contract. The NAICS code for this acquisition is 54171, Research and Development in the Physical, Engineering, and Life Sciences with a size standard of 500 employees.